NYSEMKT:IBIO iBio (IBIO) Stock Price, News & Analysis $1.78 -0.05 (-2.73%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$1.74▼$1.8450-Day Range$1.60▼$2.4152-Week Range N/AVolume39,527 shsAverage Volume113,212 shsMarket Capitalization$15.35 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartEarningsFinancialsHeadlinesInsider TradesSEC FilingsStock AnalysisChartEarningsFinancialsHeadlinesInsider TradesSEC Filings Get iBio alerts: Email Address Ad Porter & CompanyWhy billionaires are wiring money to abandoned towns A new force is brewing in these forgotten towns that could soon turn Appalachia into one of America’s most valuable economic hubs – the beating heart of a new multi-billion-dollar revolution. Click here for my exclusive video About iBio Stock (NYSEMKT:IBIO)iBio, Inc., a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel. The company is also developing vaccine candidates, including IBIO-101, an antibody to reduce tumor growth; Endostatin E4 peptide for use in chemotherapy and immunotherapy; Trop-2 for the treatment Trop-2 positive cancers; MUC16, a tumor-associated epitope; anti-EGFRvIII antibody to treat glioblastoma and other cancers; CCR8 protein candidate for treatment of various cancers; PD-1 agonist for the treatment of rheumatoid arthritis and other inflammatory diseases; and IBIO-400 for the treatment of classical swine fever. iBio, Inc. has agreement with The Texas A&M University System for designing and manufacturing of plant-made biopharmaceuticals; and a research collaboration with the National Institute of Allergy and Infectious Diseases to investigate the potential of the company's AI-driven epitope steering platform for the development of a vaccine for Lassa fever. The company was incorporated in 2008 and is headquartered in Bryan, Texas.Read More IBIO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IBIO Stock News HeadlinesSeptember 4 at 3:01 AM | americanbankingnews.comiBio (NYSEMKT:IBIO) Shares Down 4.6% August 29, 2024 | finance.yahoo.comInovio Pharmaceuticals, Inc. (INO)September 7, 2024 | Paradigm Press (Ad) Fmr CIA Advisor reveals PEACEMAKER superweaponKamala cannot get the “codes” to this superweapon. In Trump’s hands, it will restore America’s global dominance. It could also help Americans struggling under Bidenomics by potentially sending 5 military stocks SOARING. Historically, similar stocks have shot up 16,270% in just 18 months.August 28, 2024 | marketwatch.comiBio Inc. stock remains steady Wednesday, still outperforms marketAugust 25, 2024 | msn.com13F Recap Q2 2024: Klarman, Rosenstein, Miller And MoreAugust 23, 2024 | marketwatch.comiBio Inc. stock rises Friday, still underperforms marketAugust 23, 2024 | finance.yahoo.comCOSCIENS BIOPHARMA CORP. (ET8.F)August 20, 2024 | marketwatch.comiBio Inc. stock remains steady Tuesday, still outperforms marketSeptember 7, 2024 | Paradigm Press (Ad) Fmr CIA Advisor reveals PEACEMAKER superweaponKamala cannot get the “codes” to this superweapon. In Trump’s hands, it will restore America’s global dominance. It could also help Americans struggling under Bidenomics by potentially sending 5 military stocks SOARING. Historically, similar stocks have shot up 16,270% in just 18 months.August 15, 2024 | marketwatch.comiBio Inc. stock remains steady Thursday, underperforms marketAugust 15, 2024 | nz.finance.yahoo.com0JV0.SG,0P00013BY9,0 (0JV0.SG)August 9, 2024 | markets.businessinsider.comOptimistic Outlook for ProQR: Solid Financials and Promising Drug Pipeline Justify Buy RatingAugust 2, 2024 | marketwatch.comiBio Inc. stock falls Friday, underperforms marketAugust 2, 2024 | markets.businessinsider.comBuy Rating Justified by Arbutus Biopharma’s Strong Financials and Focused Clinical StrategyJuly 25, 2024 | msn.comTesla’s latest earnings expose chronically weak profitability and an inflated share priceJuly 25, 2024 | usnews.comTesla's 2Q Profit Falls 45% to $1.48 Billion as Sales Drop Despite Price Cuts and Low-Interest LoansMarch 28, 2024 | msn.comiBio, Mesoblast, Kodiak Sciences among healthcare moversMarch 27, 2024 | msn.comMicro-Cap Stock iBio Doubles On Wednesday - Here's WhySee More Headlines Receive IBIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for iBio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/15/2021Today9/07/2024Fiscal Year End6/30/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEMKT SectorMedical Industry Biotechnology Sub-IndustryPharmaceutical Products Current SymbolNYSEMKT:IBIO CUSIPN/A CIK1420720 Webwww.ibioinc.com Phone(302) 355-0650Fax302-356-1173Employees100Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-65,010,000.00 Net MarginsN/A Pretax Margin-41,546.00% Return on Equity-150.59% Return on Assets-52.83% Debt Debt-to-Equity Ratio0.04 Current Ratio0.91 Quick Ratio0.91 Sales & Book Value Annual Sales$50,000.00 Price / Sales307.01 Cash FlowN/A Price / Cash FlowN/A Book Value$2.64 per share Price / Book0.67Miscellaneous Outstanding Shares8,624,000Free Float3,445,000Market Cap$15.35 million OptionableN/A Beta-3.39 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesDr. Martin B. Brenner D.V.M. (Age 53)Ph.D., CEO & Chief Scientific Officer Comp: $577.31kMr. Felipe Duran (Age 44)Chief Financial Officer Comp: $1.07MStephen KilmerInvestor Relations OfficerMr. Marc Banjak J.D.General CounselMr. Robert B. Kay (Age 84)Interim Secretary & Interim Treasurer Comp: $92.69kKey CompetitorsEagle PharmaceuticalsNASDAQ:EGRXSunshine BiopharmaNASDAQ:SBFMCEL-SCINYSE:CVMVolitionRxNYSE:VNRXAffimedNASDAQ:AFMDView All CompetitorsInsidersMartin BrennerSold 210 sharesTotal: $1,302.00 ($6.20/share)View All Insider Transactions IBIO Stock Analysis - Frequently Asked Questions How have IBIO shares performed this year? iBio's stock was trading at $1.37 at the beginning of the year. Since then, IBIO stock has increased by 29.9% and is now trading at $1.78. View the best growth stocks for 2024 here. How were iBio's earnings last quarter? iBio, Inc. (NYSEMKT:IBIO) posted its earnings results on Monday, November, 15th. The company reported ($20.00) earnings per share (EPS) for the quarter, topping the consensus estimate of ($25.00) by $5.00. The company had revenue of $0.21 million for the quarter. When did iBio's stock split? iBio's stock reverse split on the morning of Wednesday, November 29th 2023. The 1-20 reverse split was announced on Wednesday, November 29th 2023. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, November 29th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. How do I buy shares of iBio? Shares of IBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSEMKT:IBIO) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding iBio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share iBio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.